Neogenomics
Jefferies Initiates Coverage of NeoGenomics, Hologic, QuidelOrtho
The investment bank said it prefers diagnostics companies with strong commercial engines, although noted it that Hologic and QuidelOrtho are in transition.
Mixed Month for Diagnostics Stocks as 360Dx Top 30 Ticks up 1 Percent in November
Out of the 30 companies tracked by 360Dx, 13 saw their share prices increase, while 17 saw their stock prices decline.
Pathologists See Value Balance Shift Toward Comprehensive Sequencing for Hematologic Cancers
Premium
At the AMP annual meeting last week, speakers at multiple workshops said their field is reaching a tipping point as the clinical utility of NGS further solidifies.
NeoGenomics Q3 Revenues up 10 Percent
The company attributed the growth to a rise in both test volume and revenue per test, despite slagging sales in its advanced diagnostics arm.
The company believes that it has threaded the needle in terms of providing the maximum of necessary information to clinicians, while maintaining a rapid turnaround time.
Oct 1, 2024
360Dx Top 30 Inches up 1 Percent in September
Aug 1, 2024
360Dx Top 30 Jumps 11 Percent in July
Jan 3, 2024
360Dx Top 30 Falls 5 Percent in 2023
Jul 31, 2023